These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 25734961)
21. Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction. Henry CA; Lyon RA; Ling H Vasc Health Risk Manag; 2016; 12():163-9. PubMed ID: 27143910 [TBL] [Abstract][Full Text] [Related]
22. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition. Tibolla G; Norata GD; Artali R; Meneghetti F; Catapano AL Nutr Metab Cardiovasc Dis; 2011 Nov; 21(11):835-43. PubMed ID: 21943799 [TBL] [Abstract][Full Text] [Related]
23. PCSK9 inhibition: current concepts and lessons from human genetics. Rodriguez F; Knowles JW Curr Atheroscler Rep; 2015 Mar; 17(3):487. PubMed ID: 25637042 [TBL] [Abstract][Full Text] [Related]
24. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57). Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333 [TBL] [Abstract][Full Text] [Related]
25. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction. Tavori H; Melone M; Rashid S Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1137-44. PubMed ID: 25244623 [TBL] [Abstract][Full Text] [Related]
26. Focus on alirocumab: A PCSK9 antibody to treat hypercholesterolemia. Devito F; Zito A; Ricci G; Carbonara R; Dentamaro I; Cortese F; Carbonara S; Ciccone MM Pharmacol Res; 2015 Dec; 102():168-75. PubMed ID: 26455563 [TBL] [Abstract][Full Text] [Related]
27. PCSK9 antibodies for the treatment of hypercholesterolemia. Gouni-Berthold I; Berthold HK Nutrients; 2014 Dec; 6(12):5517-33. PubMed ID: 25470376 [TBL] [Abstract][Full Text] [Related]
28. [Inhibition of the protein PCSK9 is a promising target in the prevention of cardiovascular disease]. Christiansen MK; Jensen HK Ugeskr Laeger; 2015 Mar; 177(11):. PubMed ID: 25786699 [TBL] [Abstract][Full Text] [Related]
29. The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications. Farnier M Am J Cardiovasc Drugs; 2011 Jun; 11(3):145-52. PubMed ID: 21619378 [TBL] [Abstract][Full Text] [Related]
30. Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials. Li C; Lin L; Zhang W; Zhou L; Wang H; Luo X; Luo H; Cai Y; Zeng C J Am Heart Assoc; 2015 Jun; 4(6):e001937. PubMed ID: 26077586 [TBL] [Abstract][Full Text] [Related]
39. Update of Clinical Trials of Anti-PCSK9 Antibodies. Wu NQ; Li S; Li JJ Cardiovasc Drugs Ther; 2015 Apr; 29(2):159-69. PubMed ID: 25916406 [TBL] [Abstract][Full Text] [Related]
40. [PCSK9 inhibitors. A new approach for treatment of hypercholesterolemia]. Saußele T Med Monatsschr Pharm; 2015 Jul; 38(7):250-7. PubMed ID: 26364362 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]